NICE TAs

03/12/2025

ID6294: Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

25/02/2026

TA1136: bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

11/03/2026

TA1139: Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment

02/03/2026

TA1138: Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer

25/02/2026

TA1137: canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)

19/02/2026

TA1135: Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)

18/02/2026

TA1134: Dupilumab for treating severe chronic rhinosinusitis with nasal polyps

18/02/2026

TA1133: Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma

18/02/2026

HST34: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (terminated appraisal)

18/02/2026

HST34: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2

17/02/2026

TA1132: Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)

12/02/2026

TA1129: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

12/02/2026

TA1131: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

11/02/2026

TA1130: Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer

04/02/2026

TA1128: Targeted-release budesonide for treating primary IgA nephropathy

04/02/2026

TA1127: Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer

28/01/2026

TA1126: natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

27/01/2026

TA972: sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)

27/01/2026

TA1125: pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)

27/01/2026

TA1124: concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)